Thursday, 22 September 2011

Amrutanjan to start custom manufacturing

Amrutanjan Health Care Ltd plans to offer custom manufacturing services through its fine chemicals subsidiary, Amrutanjan Pharmaessence Pvt Ltd. The company has signed a memorandum of understanding to provide contract manufacturing for Sigma Aldrich.
Business Standard

CMC Biologics will manufacture Inspiration Biopharmaceuticals' intravenous recombinant factor IX product

Pharmaceutical Business Review

Tuesday, 20 September 2011

Lonza plans Singapore listing

Lonza will list on the Singapore stock exchange later this year. The secondary listing on the Main Board of the Singapore Exchange Securities Trading Limited is designed to give the company a more visible presence in Asia, allowing it to tap the strong capital flows in Asia, and enlarging and broadening its current investor base in the region, said Stehan Borgas, Lonza's ceo.
Channel News Asia

Thursday, 15 September 2011

Lonza will manufacture Pasteuria Bioscience's Pasteuria spores at its KouŢim microbial fermentation facility


Jubilant's $70m contract

Jubilant Life Sciences' Jubilant HollisterStier facility in Montreal, Canada, will manufacture a product for a US pharma company. The deal is worth $70m over the next four years. Economic Times

Warning letter for Lonza

Lonza has received an FDA warning letter following cGMP violations in the production of Eisai's Ontak at its Hopkinton, MA, facility. Lonza received the letter after failing to address issues raised in inspections during April and May. The FDA cited Lonza for inadequate or lack of an investigation of critical deviations or a failure of a batch to meet its specifications or quality standards; failure to validate analytical test methods used for API for potency testing; and failure of its quality unit to exercise its responsibility to ensure that APIs manufactured are in compliance with CGMP, including meeting established specifications for quality and purity. In-pharma Technologist

Albemarle is to increase prices for generic APIs by 8-12%, depending on the specific product, from 15 October


Wednesday, 7 September 2011

Oxford BioTherapeutics has licensed CMC Biologics’ CHEF1 expression system for research, development, and commercial use

Oxford BioTherapeutics

Lonza and Fosun to establish jv

Lonza and Shanghai Fosun Pharmaceutical plan to create a jv in Pudong Zhangjiang High-Tech Industry Zone. The two companies will jointly invest CNY100m ($15.6m). Lonza has said that five drugs will be produced by the jv. Capital Vue

Camlin Fine Chemicals has been renamed Camlin Fine Sciences

Bombay Stock Exchange

Oxford BioTherapeutics has licensed Lonza’s GS Gene Expression System for research, development and commercial applications

Oxford BioTherapeutics

CMC Biologics has completed the installation of a 2000L single-use bioreactor at its Copenhagen manufacturing facility

PR Newswire

Fareva acquires Pfizer plant

Fareva has acquired Pfizer's Henrico, VA, plant and will invest $42m in the facility. Fareva will keep the current 500 employees at the facility and planes to add more over the next five years. As part of the agreement, Fareva will manufacture products for Pfizer for six years. Richmond Times-Dispatch

DSM and Sinochem anti-infectives jv

DSM has established a Hong Kong-based 50/50 global joint venture for its business anti-Iinfectives with Sinochem. Under the jv agreement Sinochem has paid €210m for a 50% equity interest in the business group. The new organisation will be called DSM Sinochem Pharmaceuticals Limited. DSM

Sales grow for Siegfried

Siegfried reported a 28.3% rise in sales to CHF173.8m in H1 2011. Siegfried attributed the growth to a significant increase in API sales, particularly in exclusive synthesis. The company said its strategy is on track and it has the necessary funds for implementation of the strategy. Siegfried

BASF has increased prices of APIs and excipients by 10% due to rising costs for raw materials, energy and labour

In-pharma Technologist